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Abstract
AIM: To assess the immunoexpression of hypoxia-
related markers in samples from cirrhosis and primary 
and metastatic hepatocellular carcinoma (HCC).
METHODS: From a total of 5836 autopsies performed 
at the Pathology Department - University of Sao Paulo 
School of Medicine Hospital - from 2003 to 2009, 188 
presented primary liver tumors. Immunohistochemical 
reactivity for monocarboxylate transporters (MCTs)-1, 
2 and 4, CD147 and glucose transporter-1 (GLUT1) 
was assessed in necropsies from 80 cases of HCC. Data 
were stored and analyzed using the IBM SPSS statistical 
software (version 19, IBM Company, Armonk, NY). All 
comparisons were examined for statistical significance 
using Pearson’s χ 2 test and Fisher’s exact test (when n  
< 5). The threshold for significant P values was estab-
lished as P  < 0.05.
RESULTS: Plasma membrane expression of MCT4 and 
overall expression of GLUT1 showed progressively high-
er expression from non-neoplastic to primary HCC and 
to metastases. In contrast, overall expression of MCT2 
was progressively decreased from non-neoplastic to pri-
mary HCC and to metastases. MCT1 (overall and plas-
ma membrane expression), MCT2 and CD147 plasma 
membrane expression were associated with absence of 
cirrhosis, while plasma membrane expression of CD147 
was also associated with absence of HBV infection. 
MCT2 overall expression was associated with lower liver 
weight, absence of metastasis and absence of abdomi-
nal dissemination. Additionally, MCT4 plasma membrane 
positivity was strongly associated with Ki-67 expression. 
CONCLUSION: MCT4 and GLUT1 appear to play a role 
in HCC progression, while MCT2 is lost during progres-
sion and associated with better prognosis. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This paper describes, for the first time, the 
role of monocarboxylate transporters in hepatic car-
cinoma. The characterization of monocarboxylate 
transporter activity in acidic metabolism of primary and 
metastatic hepatocellular carcinoma microenvironment 
was studied in necropsy material and allowed us to 
precisely evaluate the impact of the more acidic micro-
environment that is potentially maintained by monocar-
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INTRODUCTION
Oxygen is the essential final electron acceptor of  energy 
metabolism. Under physiological conditions, the mean 
oxygen tension (dissolved free oxygen concentration) 
is 74-104 mmHg in arterial blood and 34-46 mmHg in 
venous blood. The “double vascular pattern” in the liver 
results in a physiological oxygen tension gradient, from 
60-65 mmHg in peri-portal blood falling to approximate-
ly 30-35 mmHg in centrilobular regions, thus rendering 
liver parenchyma especially vulnerable to hypoxia[1]. Hy-
poxia inducible factor 1α (HIF-1 α) is the major regula-
tor hypoxia modulation and targets many enzymes of  
the glycolytic pathway, including glucose transporter-1 
(GLUT1), lactate dehydrogenase A (LDH-A) and mono-
carboxylate transporters, and especially monocarboxylate 
transporter (MCT)-4[2,3] .
The microenvironment of  solid tumors tends to be-
come acidic due to the high rate of  glycolysis maintained 
by cancer cells, thus resulting in the production of  high 
amounts of  lactate and leading to acidification of  the 
extracellular milieu[3]. Warburg[4] was the first to suggest 
that cancer cells prioritize the glycolytic pathway for en-
ergy production, even in the presence of  sufficient oxy-
gen, a phenomenon that is now known as the “Warburg 
effect”. 
MCTs have been recognized to play a key role in the 
maintenance of  this glycolytic metabolism by mediating 
lactate efflux from cancer cells. Overexpression of  one 
or more MCT isoforms, especially MCT1 and MCT4, has 
been implicated in tumor prognosis, and MCTs have thus 
been suggested as potential therapeutic targets[3,5]. Our 
group has been studying the expression of  these MCT 
isoforms as well as their chaperone, CD147, known to be 
essential for MCT activity and plasma membrane expres-
sion, in different types of  human cancers[3]. We found up-
regulation of  MCT1 and MCT4 in the plasma membrane 
of  colorectal cancer[6], upregulation of  MCT1, MCT4 
and CD147 in cervical cancer[7,8], upregulation of  MCT1 
in breast cancer[9] and upregulation of  MCT1 and CD147 
in glioblastomas[5], when compared to the corresponding 
non-neoplastic tissues. In contrast, there was a downreg-
ulation of  MCT4 in gastric cancer[10] and a downregula-
tion of  MCT1 and CD147 in prostate cancer[11]. We also 
found important associations between MCT overexpres-
sion and the clinicopathological data of  the cases, mostly 
with aggressiveness parameters[3,12-14].
Considering the susceptibility of  liver to hypoxia, the 
growing relevance of  hepatocellular carcinoma (HCC) 
worldwide[15,16] and the potential impact of  MCTs in the 
development of  several solid tumors, we sought herein to 
investigate the expression of  MCT1, 2 and 4, the MCT 
chaperone CD147 and the glycolytic marker GLUT1 in 
a necropsy series of  73 well-characterized cases of  ad-
vanced HCC and corresponding non-neoplastic samples, 
searching for a possible role of  glycolytic metabolism in 
the development of  advanced hepatocellular carcinoma. 
MATERIALS AND METHODS
Autopsy samples and data 
From a total of  5836 autopsies performed at the Pathol-
ogy Department - University of  Sao Paulo School of  
Medicine Hospital - from 2003 to 2009, 188 presented 
primary liver tumors. Excluding 65 cholangiocarcinomas, 
one combined hepatocholangiocarcinoma, one epitheli-
oid hemangioendothelioma and 13 other malignant neo-
plasms, 108 cases were diagnosed as HCC. A review of  
these cases was performed in accordance with the inves-
tigative protocols of  the Institutional Review Boards of  
the University of  Sao Paulo’s School of  Medicine as part 
of  the doctoral thesis recently presented by one of  the 
authors[17]. Sufficient viable tissue samples as well as clini-
cal data (gender, age, viral hepatitis, alcoholism, previous 
treatment) from medical records and from autopsy re-
ports were retrieved in 80 HCC cases. Detailed pathologi-
cal data were recorded - liver weight, gross appearance, 
number/size of  primary tumors or metastases and large 
portal or hepatic vein invasion - and complemented by 
slide review (histological grade and pattern). Paraffin tis-
sue blocks from these 80 HCC cases were used for tissue 
microarray (TMA) construction and immunohistochem-
istry studies.
TMA construction
Primary HCC and extra-hepatic metastasis samples were 
selected upon microscopic review (ASFS) and 3 cores of  
each sample were spotted in two TMAs (1.0 mm cores). 
For heterogeneous tumors, different areas were separately 
cored. When more than one primary HCC was present 
in a single case, all tumors were sampled, but data were 
computed for the largest one. Fewer spots were used only 
when the size of  the metastasis was limiting (< 0.5 cm). 
Available non-neoplastic liver samples were selected as 
far from the tumor border as possible, usually in a differ-
ent paraffin block, and cored in one TMA. 
Immunohistochemistry reactions
Primary antibodies: As depicted in Table 1, primary 
antibodies against MCT1, MCT2, MCT4, CD147, and 
GLUT1 were standardized in our laboratory, as previ-
ously published[6,8,12]. 
Briefly, deparaffinized and rehydrated sections were 
subjected to specific conditions of  heat-induced antigen 
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retrieval. After inactivation of  endogenous peroxidases, 
tissue sections were incubated with protein blocking solu-
tion for 20 min and incubated with the primary antibody 
under the conditions specified in Table 1. Sections were 
then sequentially washed in PBS and incubated with 
biotinylated secondary antibody and enzyme-coupled 
reagent from R.T.U. Vectastain® Elite ABC (Burlingame, 
CA, United States) for MCT1 and CD147 or Ultravision 
Detection System Anti-polyvalent, HRP (Lab Vision Cor-
poration, Fremont, CA) for MCT2, MCT4 and GLUT-1. 
All reactions were developed with 3,3’-diamino-benzidine 
(DAB+ Substrate System, DakoCytomation, Carpinteria, 
CA, United States) for 10 min. Negative controls were 
performed by using an appropriate serum control for 
the primary antibodies (n1698, DakoCytomation, Car-
pinteria, CA, United States) and colon carcinoma tissue 
was used as a positive control for MCT1, MCT2, MCT4 
and CD147, and squamous cell laryngeal carcinoma for 
GLUT1. All tissue sections were counterstained with he-
matoxylin and permanently mounted. Immunoreactions 
for EGFR, Ki-67, Keratin 19 (putative markers of  molec-
ular classification of  HCC recently proposed by Hoshida 
et al[18]) as well as for the apoptosis marker Caspase 3 were 
previously performed[17] and were herein compared to 
MCTs expression. 
Immunohistochemical evaluation
Sections were semi-quantitatively scored for immunore-
action as follows: 0: 0% of  immunoreactive cells; 1: < 5% 
of  immunoreactive cells; 2: 5%-50% of  immunoreactive 
cells; and 3: > 50% of  immunoreactive cells. Additionally, 
staining intensity was scored semi-qualitatively as follows: 
0: negative; 1: weak; 2: intermediate; and 3: strong. The 
final score was defined as the sum of  both parameters 
(extent and intensity) and grouped as negative (score 0 
and 2) and positive (score 3-6), as previously described[6]. 
Because being located in the plasma membrane is es-
sential for the activity of  these proteins, the presence 
of  plasma membrane expression of  MCTs, CD147 and 
GLUT1 was recorded. Immunohistochemical assessment 
was blindly performed by two independent observers 
(VAFA and ASFS) and discordant cases were discussed 
using a double-head microscope in order to determine 
the final score. 
The semi-quantitation of  each marker presented 
above was compared with the clinical-pathological vari-
ables and with the quantitative assessment of  EGFR, 
Ki-67 and caspase 3 expression[17]. EGFR semi-quantita-
tion assessed both the percentage of  positive cells (0-100) 
and intensity of  staining (1-3), thus leading to the score 
0-300 and to the categories: negative < 10, positive ≥ 10 
and positive ≥ 200 (hyper-expression), as recently pub-
lished[19]. Ki67 values were assessed after counting 1000 
cells; and caspase 3 expression was considered positive 
when more than 10 bodies were stained/10 HPF; or “loss 
of  expression” (negative) when 10 or less bodies were 
stained/10 HPF. Keratin 19 expression was dichotomized 
in Positive or Negative reaction.
Statistical analysis
Data were stored and analyzed using the IBM SPSS statis-
tical software (version 19, IBM Company, Armonk, NY). 
All comparisons were examined for statistical significance 
using Pearson’s χ 2 test and Fisher’s exact test (when n < 5). 
The threshold for significant P values was established as 
P < 0.05.
RESULTS
Figure 1 illustrates positive immunoreactions for the dif-
ferent markers analyzed in the different hepatic lesions. 
Data presented in Tables 2 and 3 show that the proteins 
were found in both the cytoplasm and the plasma mem-
brane regions of  cancer cells, at different frequencies. All 
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Table 1  Immunohistochemistry protocols used to characterize the proteins expression
Code Industry Dilution Epitope retrieval Amplification system
MCT1 
(sc-365501)
Santa Cruz Biotechnology, Santa Cruz, 
CA, United States
1:500 EDTA (1 mmol/L, pH = 8); Vectastain® Elite ABC reagent
98 ℃; 20 min (Burlingame, CA, United States)
MCT2 
(sc-14926)
Santa Cruz Biotechnology, Santa Cruz, 
CA, United States
1:200 Citrate buffer (10 mmol/L, 
pH = 6); 98 ℃; 20 min
Ultravision Detection System Anti-polyvalent, HRP, 
Lab Vision Corporation, Fremont, CA, United States)
MCT4 
(sc-50329)
Santa Cruz Biotechnology, Santa Cruz, 
CA, United States
1:500 Citrate buffer (10 mmol/L, 
pH = 6); 98 ℃; 20 min
Ultravision Detection System Anti-polyvalent, HRP, 
Lab Vision Corporation, Fremont, CA, United States)
CD147 
(sc-71038)
Santa Cruz Biotechnology, Santa Cruz, 
CA, United States
1:400 EDTA (1 mmol/L, pH = 8); Vectastain® Elite ABC reagent (Burlingame, CA, 
United States)98 ℃; 20 min
GLUT1 
(ab15309)
Abcam, Cambridge, United Kingdom 1:500 Citrate buffer (10 mmol/L, 
pH = 6); 98 ℃; 20 min
Ultravision Detection System Anti-polyvalent, HRP, 
Lab Vision Corporation, Fremont, CA, United States)
Caspase 3 Diagnostic BioSystems (DBS) Pleasanton, 
CA, United States
1:160 Citrate buffer (10 mmol/L, 
pH = 6); 98 ℃; 40 min
NovoLink (Novocastra Laboratories Ltd, Newcastle 
Upon Tyne, United Kingdom)(3C SP03)
Keratin 19
(K19, b170)
Novocastra Laboratories Ltd, Newcastle 
Upon Tyne, United Kingdom
1:300 Citrate buffer (10 mmol/L, 
pH = 6); 98 ℃; 40 min
NovoLink (Novocastra Laboratories Ltd, Newcastle 
Upon Tyne, United Kingdom)
Ki-67 
(MIB-1)
(Dako, Glostrup, Denmark) 1:400 Citrate buffer (10 mmol/L, 
pH = 6); 98 ℃; 40 min
NovoLink (Novocastra Laboratories Ltd, Newcastle 
Upon Tyne, United Kingdom)
EGFR human 
(DAK-H1-WT)
(Dako, Glostrup, Denmark) 1:200 Citrate buffer (10 mmol/L, 
pH = 6); 98 ℃; 40 min
NovoLink (Novocastra Laboratories Ltd, Newcastle 
Upon Tyne, United Kingdom)
MCT: Monocarboxylate transporter; GLUT: Glucose transporter; EGFR: Epidermal growth factor receptor.
Alves VA et al . MCTs in hepatocellular carcinoma
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Table 2  Association of overall expression of cell metabolism markers with the neoplastic (including metastasis) and non-neoplastic 
status of the liver  n  (%)
MCT1 MCT2 MCT4 CD147 GLUT1
n Positive P value n Positive P value n Positive P value n Positive P value n Positive P value
Non-neoplastic 26 25 (96.2) 26 23 (88.5) 26   3 (11.5) 26 22 (84.6) 26 0 (0.0)
Primary tumor 73 46 (63.0) 74 52 (70.3) 76 31 (40.8) 75 36 (48.0) 76 7 (9.2)
Metastasis 16   9 (56.2) 16   6 (46.2) 17 11 (64.7) 17 10 (58.8) 17   5 (29.4)
0.003 0.02 0.001 0.005 0.007
MCT: Monocarboxylate transporter; GLUT: Glucose transporter.
Table 3  Association of the plasma membrane expression of cell metabolism markers with the neoplastic (including metastasis) and 
non-neoplastic status of the liver  n  (%)
MCT1 MCT2 MCT4 CD147 GLUT1
n Positive P value n Positive P value n Positive P value n Positive P value n Positive P value
Non-neoplastic 26 25 (96.2) 26 0 (0.0) 26 1 (3.8) 26 20 (76.9) 26 0 (0.0)
Primary tumor 73 40 (54.8) 74   9 (12.2) 76 29 (38.2) 75 32 (42.7) 76 4 (5.3)
Metastasis 16   9 (56.2) 16 1 (7.7) 17   8 (47.1) 17   9 (52.9) 17   3 (17.6)
0.001 0.169 0.002 0.011 0.052
MCT: Monocarboxylate transporter; GLUT: Glucose transporter.
Figure 1  Representative positive immunoreactions. A: Hepatocellular carcinoma (HCC); B: Monocarboxylate transporter 1 (MCT1); C: MCT2; D: MCT4; E: 
CD147; F: Glucose transporter 1. Original magnification 400 ×.
A
B
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of  the markers were more highly expressed at the plasma 
membrane, with the exception of  MCT2, which was ex-
pressed at a higher level in the cytoplasm. Importantly, 
expression of  both MCT4 and GLUT1 were progres-
sively increased from non-neoplastic to primary HCC, 
reaching a maximum frequency in metastases (Tables 2 
and 3). In contrast, MCT2 expression was progressively 
decreased from non-neoplastic to primary HCC, reaching 
a minimum frequency in metastases (Table 3). MCT1 and 
CD147 were also significantly different among the hepat-
ic lesion groups, showing a higher expression in the non-
neoplastic samples compared to primary HCC and me-
tastasis (Tables 2 and 3). Additionally, plasma membrane 
expression of  MCT1, but not MCT4 or MCT2, was as-
sociated with plasma membrane expression of  CD147 (P 
< 0.001; Table 4), while plasma membrane expression of  
MCT4 was associated with plasma membrane expression 
GLUT1 (P = 0.004; Table 4).
No significant association of  the total expression or 
plasma membrane expression of  MCTs with the clinical-
pathological data was observed. Examinations of  the re-
lationships between total and plasma membrane expres-
sion of  CD147 and GLUT1 with the clinical-pathological 
data have shown that the gender and architectural pattern 
of  the lesions are important factors in these associa-
tions. MCTs, CD147 and GLUT1 were not associated 
with EGFR, Ki-67 and Keratin 19, which are important 
markers in a recently proposed molecular classification 
of  HCC[18]. Associations of  MCTs, CD147 and GLUT1 
with the apoptosis marker caspase 3, were not significant 
as well. The exception was the significant correlation 
between MCT4 expression and Ki-67 counting. MCT1 
expression, both in cytoplasm and plasma membrane, 
was higher in the absence of  cirrhosis (P = 0.044 and P 
= 0.015, respectively). Cytoplasmic MCT2 positive stain-
ing was associated with liver weight lower than 1.5 kg (P 
= 0.027), absence of  distant metastasis (P = 0.036) and 
absence of  abdominal dissemination (P = 0.010), while 
plasma membrane MCT2, similar to MCT1, was associat-
ed with absence of  cirrhosis (P = 0.036). Despite the fact 
that MCT4 did not correlate with the clinical-pathological 
variables assessed herein, MCT4 expression in the plasma 
membrane was strongly associated with Ki-67 positivity (P 
= 0.004) and also tended to associate with K19 expres-
sion (P = 0.087). CD147 plasma membrane expression 
was more frequent in HCC unrelated to cirrhosis (P = 
0.038). Additionally, cytoplasmic (P = 0.008) and plasma 
membrane (P = 0.005) CD147 positive staining were 
associated with the absence of  HBV infection. Finally, 
GLUT1 positive expression was higher in HCC affect-
ing women (P = 0.041 for cytoplasmic positivity and P = 
0.033 for membrane positive reaction). 
DISCUSSION
The role of  MCTs in tumor biology has been explored in 
recent years[3,6-9]. We have previously addressed MCTs ex-
pression in different malignancies compared to respective 
non-neoplastic parenchyma[3,6-9,10-12,20]. From those studies, 
we have learned that members of  the MCT family may 
behave heterogeneously in each type of  tumor and, espe-
cially MCT1 and/or MCT4, are highly expressed selected 
and, in some of  them, are associated with worse prognos-
tic markers[11,12,21]. Additionally, in vitro and in vivo evidence 
favors the hypothesis that some MCT isoforms might 
even be considered potential therapeutic targets[5,22,23]. 
The present study is the first to assess the possible 
role of  MCTs in hepatocellular carcinoma. Our decision 
to approach our large autopsy series of  HCC in this first 
study before assessing our series of  biopsies or surgical 
specimens was based on the unique opportunity to com-
pare MCT expression in non-neoplastic vs primary vs 
metastatic HCCs. However, inherent to autopsy studies, 
many of  the tumors of  the present series were advanced, 
thus reducing the impact of  the assessment of  clinical-
laboratorial variables that might reflect initial steps of  
hepatocarcinogenesis. Because molecular integrity is not 
always assured in autopsy specimens, we did not per-
form mRNA studies, but the positive and negative con-
trols performed herein assure that protein preservation 
was good enough to yield reliable immunohistochemical 
studies.
The most frequent patterns of  HCC, as studied in 
the present necropsy series, show only a minor stromal 
component; therefore, in the current study, we did not 
particularly focus on stroma. Future studies should spe-
cifically address stromal-rich HCC subtypes, especially 
fibrolamellar HCC and sclerosing HCC.
The observed activity of  MCTs 1, 2 and 4, CD147 
and GLUT1 in HCC is partially aligned with most of  
our previous observations in adenocarcinomas from 
other organs[3]. Membrane expression of  MCT4 and, less 
frequently, GLUT1 was found almost restricted to neo-
plastic liver and was higher in metastases. MCT4 expres-
sion was significantly related to a higher Ki-67 Ag index 
and also tended to associate with K19 expression (data 
not shown). Also, MCT4 was more frequent in higher 
histological grades (36.4% in g.1, 37.2% in g.2 and 63.6% 
in g.3), although this relationship was not statistically 
CD147 GLUT1
n Positive P value n Positive P value
MCT1 < 0.001 1.000
Negative   40   4 (10.0)   40 2 (5.0)
Positive   74 56 (75.7)   74 4 (5.4)
MCT2    0.766 0.434
Negative 102 56 (54.9) 103 5 (4.9)
Positive   10   5 (50.0)   10   1 (10.0)
MCT4    0.114 0.004
Negative   80 46 (57.5)   81 1 (1.2)
Positive   36 15 (41.7)   38   6 (15.8)
Table 4  Association of the plasma membrane expression of 
monocarboxylate transporters with the plasma membrane 
expression of the chaperone CD147 and the glycolytic 
protein glucose transporter 1  n  (%)
MCT: Monocarboxylate transporter; GLUT: Glucose transporter.
Alves VA et al . MCTs in hepatocellular carcinoma
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significant. These relevant data link MCT4 activity with 
high proliferative index and possibly to the “progenitor 
cell component” of  HCC, pointing to a role of  MCT4 in 
HCC progression and/or more aggressive course.
As previous studies have extensively shown, the tran-
sition from high-grade dysplastic nodule to early HCC, as 
well as from “small, well-differentiated, indistinct border 
HCC” to “progressed HCC”, runs in parallel with an 
abrupt shift in the vascular pattern[24]. We speculate that 
this fact could lead to important neo-angiogenesis that 
is immunohistochemically identified by diffusely CD34-
positive microvessels, which might correspond to the 
shift to a preferably glycolytic pattern of  energy source 
through the Warburg effect. At this point, MCT4 and 
GLUT1 would become overexpressed, in accordance 
with previous evidence that MCT4 is highly expressed 
in response to hypoxia, mostly mediated by HIF-1 α[3,25]. 
Interestingly, due to the double arterial and portal vein 
blood inflow, the liver is per se an organ normally exposed 
to “hypoxia”, which is potentiated in cirrhosis and in 
malignant transformation[26]. In the cirrhotic liver, inflam-
mation, hepatocytic lesion formation and regeneration, 
and neo-vessel formation are associated with the hypoxic 
setting, and stem cell activation is stimulated because 
these cells are able to resist this acidic/hypoxic microen-
vironment where cancer development and progression 
are strongly favored[24]. In livers chronically infected by 
HBV and HCV, the consequent cirrhosis is associated 
with a remarkable decrease in oxygen supply and, as such, 
the microenvironment induces stabilization of  HIF-1α, 
which promotes angiogenesis by activating the transcrip-
tion of  vascular endothelial growth factor and cyclooxy-
genases and activating matrix metalloproteinases[26]. In 
summary, hypoxia induces cell damage and inflammation, 
limits liver regeneration and is strongly associated with 
HCC development[27]. Additionally, hypoxia was proved 
to be associated with glycolysis upregulation[28]. This 
result was partially demonstrated in the present study, 
as MCT4 and GLUT1 were more frequently expressed 
in primary HCC and metastasis than in non-neoplastic 
hepatocytes, thus corroborating previous evidence that 
GLUT1 is not detectable in normal epithelial tissues and 
benign epithelial neoplasms[28,29]. GLUT1 expression was 
previously demonstrated to be increased in HCC and 
promotes hepatic carcinogenesis[29].
MCT1 and its chaperone CD147, as well as MCT2, 
were found in this study to be more frequently expressed 
in non-neoplastic tissue than in HCC. Among the hepa-
tocellular carcinomas, these proteins were significantly 
most commonly expressed in cases not related to HBV 
infection and in those occurring in non-cirrhotic livers. 
These observations warrant additional studies. This evi-
dence points to the possible important role of  MCT1 
and CD147, and possibly MCT2, in the liver cell energy 
system. In contrast, MCT4 seems to be responsible for 
maintaining the glycolytic and acid resistant phenotype 
of  cancer cells during the progression of  HCC, with 
higher expression in advanced stages. In this context, it is 
important to highlight that while MCT4 affinity for the 
substrate makes this protein a transporter specialized in 
lactate efflux, MCT1 affinity for the substrate allows this 
isoform to promote both uptake and efflux of  lactate. 
Therefore, the expression of  MCT1, associated with its 
chaperone CD147, in non-neoplastic hepatic tissue may 
be related to one or both lactate transport directions, but 
most likely with the uptake of  lactate because this tissue 
is a gluconeogenic tissue. Following this rationale, it was 
also expected to find plasma membrane expression of  
MCT2 (the isoform specialized for substrate uptake) in 
non-neoplastic hepatic tissue, as previously described for 
normal liver[25]. However, plasma membrane expression 
of  MCT2 was not found in non-neoplastic tissue. Instead, 
MCT2 was highly expressed in the cytoplasm of  non-
neoplastic tissue and progressively decreased towards me-
tastasis. This important cytoplasmic expression of  MCT2 
might be related to mitochondrial pyruvate transport, as 
MCTs were already described to be present in the mito-
chondria[30]. Because the metabolic behavior of  liver cells 
in cancer will be adapted towards glucose consumption 
instead of  glucose production, the expression of  MCT2 
will no longer be required, explaining the progressive de-
crease of  MCT2 expression in the cytoplasm. In fact, the 
portion of  tumors that maintains MCT2 expression in 
the cytoplasm should have a metabolism more similar to 
that found in normal tissues and therefore be less aggres-
sive. This result explains the association between MCT2 
cytoplasmic expression and variables related to a less 
aggressive profile, such as lower liver weight, absence of  
metastasis and absence of  abdominal dissemination.
Interestingly, the increase in plasma membrane ex-
pression of  MCT4 was not accompanied by CD147, 
similar to what was observed and expected for MCT2, 
but in contrast to what was observed for MCT1 (since, 
as expected, MCT1 was co-expressed with CD147). 
This information points to the existence of  another 
MCT chaperone, as already hypothesized by our group 
in other studies[20]. Therefore, further studies will be 
important to search for the additional MCT chaper-
one, as it is essential for MCT activity and may also be 
regulating its expression. It is important to emphasize 
that MCTs and their chaperones are predominantly 
expressed in plasma membrane, their natural location, 
in both normal and neoplastic cells. Thus, it is not sur-
prising that the hyper-expression of  MCTs and CD147 
corresponded more consistently with clinical data in dif-
ferent solid tumors[3].
In conclusion, our results assessed for the first time 
the role of  MCTs in the liver and in HCC. In the present 
autopsy series, mostly representative of  advanced HCC, 
MCT4 and GLUT1 were progressively highly expressed 
from non-neoplastic to primary HCC to metastatic 
hepatocellular carcinoma, in contrast to MCT2 that de-
creased towards malignancy and was associated with less 
advanced tumors. In addition to pointing to an impor-
tant role of  the hypoxia pathways in the progression of  
HCC, these data might add HCC to the list of  possible 
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beneficiaries of  anti-MCT therapies. Moreover, MCT4 
was strongly associated with augmented Ki-67 expres-
sion, showing also a relevant trend to association with the 
“progenitor-cell component-related” keratin 19 and to 
higher histological grades. Future studies should further 
assess morphologically and molecularly the interactions 
related to the hypoxia and metabolic pathways in the de-
velopment of  HCC, especially approaching surgical sam-
ples representative of  the sequence cirrhosis - dysplastic 
nodules - HCC.
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